Multicenter prospective study on multivariant diagnostics of
autoimmune bullous dermatoses using the BIOCHIP technology

J 2020

Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

VAN BEEK, Nina; Stine KRÜGE; Tarek FUHRMANN; Susanne LEMCKE; Stephanie GOLETZ et al.

Základní údaje

Originální název

Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

Autoři

Vydání

Journal of the American Academy of Dermatology, New York, MOSBY-ELSEVIER, 2020, 0190-9622

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.527

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116748

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

autoimmune bullous diseases; biochip; immunofluorescence; pemphigoid; pemphigus

Štítky

14110125, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 1. 2021 13:57, Mgr. Tereza Miškechová

Anotace

V originále

Background: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lubeck. Results: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen k for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations: Laminin 332 and laminin gamma 1 are not represented on the BIOCHIP Mosaic. Conclusions: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.

Citovat

VAN BEEK, Nina; Stine KRÜGE; Tarek FUHRMANN; Susanne LEMCKE; Stephanie GOLETZ; Christian PROBST; Lars KOMOROWSKI; Giovanni DI ZENZO; Marian DMOCHOWSKI; Kossara DRENOVSKA; Michael HORN; Hana JEDLIČKOVÁ; Cezary KOWALEWSKI; Ljiljana MEDENICA; Dedee MURRELL; Aikaterini PATSATSI; Shamir GELLER; Soner UZUN; Snejina VASSILEVA; Xuejun ZHU; Kai FECHNER; Detlef ZILLIKENS; Winfried STÖCKER; Enno SCHMIDT a Kristin RENTZSCH. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. Journal of the American Academy of Dermatology. New York: MOSBY-ELSEVIER, 2020, roč. 83, č. 5, s. 1315-1322. ISSN 0190-9622. Dostupné z: https://doi.org/10.1016/j.jaad.2020.01.049.

@article{1687458,
   author = {van Beek, Nina and Krüge, Stine and Fuhrmann, Tarek and Lemcke, Susanne and Goletz, Stephanie and Probst, Christian and Komorowski, Lars and Di Zenzo, Giovanni and Dmochowski, Marian and Drenovska, Kossara and Horn, Michael and Jedličková, Hana and Kowalewski, Cezary and Medenica, Ljiljana and Murrell, Dedee and Patsatsi, Aikaterini and Geller, Shamir and Uzun, Soner and Vassileva, Snejina and Zhu, Xuejun and Fechner, Kai and Zillikens, Detlef and Stöcker, Winfried and Schmidt, Enno and Rentzsch, Kristin},
   article_location = {New York},
   article_number = {5},
   doi = {https://doi.org/10.1016/j.jaad.2020.01.049},
   keywords = {autoimmune bullous diseases; biochip; immunofluorescence; pemphigoid; pemphigus},
   language = {eng},
   issn = {0190-9622},
   journal = {Journal of the American Academy of Dermatology},
   title = {Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology},
   url = {https://www.sciencedirect.com/science/article/pii/S019096222030133X},
   volume = {83},
   year = {2020}
}

TY  - JOUR
ID  - 1687458
AU  - van Beek, Nina - Krüge, Stine - Fuhrmann, Tarek - Lemcke, Susanne - Goletz, Stephanie - Probst, Christian - Komorowski, Lars - Di Zenzo, Giovanni - Dmochowski, Marian - Drenovska, Kossara - Horn, Michael - Jedličková, Hana - Kowalewski, Cezary - Medenica, Ljiljana - Murrell, Dedee - Patsatsi, Aikaterini - Geller, Shamir - Uzun, Soner - Vassileva, Snejina - Zhu, Xuejun - Fechner, Kai - Zillikens, Detlef - Stöcker, Winfried - Schmidt, Enno - Rentzsch, Kristin
PY  - 2020
TI  - Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
JF  - Journal of the American Academy of Dermatology
VL  - 83
IS  - 5
SP  - 1315-1322
EP  - 1315-1322
PB  - MOSBY-ELSEVIER
SN  - 01909622
KW  - autoimmune bullous diseases
KW  - biochip
KW  - immunofluorescence
KW  - pemphigoid
KW  - pemphigus
UR  - https://www.sciencedirect.com/science/article/pii/S019096222030133X
L2  - https://www.sciencedirect.com/science/article/pii/S019096222030133X
N2  - Background: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lubeck. Results: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen k for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations: Laminin 332 and laminin gamma 1 are not represented on the BIOCHIP Mosaic. Conclusions: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.
ER  -

VAN BEEK, Nina; Stine KRÜGE; Tarek FUHRMANN; Susanne LEMCKE; Stephanie GOLETZ; Christian PROBST; Lars KOMOROWSKI; Giovanni DI ZENZO; Marian DMOCHOWSKI; Kossara DRENOVSKA; Michael HORN; Hana JEDLIČKOVÁ; Cezary KOWALEWSKI; Ljiljana MEDENICA; Dedee MURRELL; Aikaterini PATSATSI; Shamir GELLER; Soner UZUN; Snejina VASSILEVA; Xuejun ZHU; Kai FECHNER; Detlef ZILLIKENS; Winfried STÖCKER; Enno SCHMIDT a Kristin RENTZSCH. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. \textit{Journal of the American Academy of Dermatology}. New York: MOSBY-ELSEVIER, 2020, roč.~83, č.~5, s.~1315-1322. ISSN~0190-9622. Dostupné z: https://doi.org/10.1016/j.jaad.2020.01.049.

Přehled o publikaci